Figure 6.

Protective effects induced by intranasal administration of rZEIII-FLIPr. Groups of immunodeficient AG129 mice (n = 9/group) were intranasally administered PBS, rZEIII, or rZEIII-FLIPr (30 μg per dose) 3 times at two-week intervals. All animals were intraperitoneally injected with 80 FFUs of Zika virus (PRVABC59) in 0.2 mL of PBS at 6 weeks after the first administration. (A) Plasma and (B) VL samples were collected 3 and 4 days after virus challenge, respectively. The viral titers were evaluated by focus-forming assays. The viral titers were logarithmically transformed before statistical analyses. Data represent the mean ± SE of the mean. Statistical significance was determined using the Kruskal-Wallis test with Dunn’s multiple comparison test. ***p<0.001. (C) The overall survival of the mice is shown. Survival analysis was calculated by Log-Rank test. *p < 0.05. **p < 0.01.